AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights:
-
IQ-AI Ltd is nearing completion of its Phase I clinical trial for the IB003 cancer treatment, with only two patients remaining to enroll.
-
Preparations are underway for a meeting with the US Food and Drug Administration (FDA) to discuss the treatment’s development and the significance of its Rare Pediatric Disease Designation.
-
Progress in the Expanded Access Program (EAP) has been made, with three active sites in the US and two patients already receiving treatment.
IQ-AI Ltd (LSE:IQAI) has announced that it is nearing the completion of its Phase I clinical trial for IB003, a gallium maltolate therapy aimed at treating brain cancer in children. With only two patients left to enroll, the company is poised to transition into Phase II, which will involve a larger group of participants. This next phase is crucial for assessing the treatment's effectiveness, building on early data indicating safety and positive signs of success.
In a recent letter to shareholders, Michael Schmainda, CEO of the company's Imaging Biometrics arm, provided updates on these advancements, noting that preparations are already in progress for an important meeting with the US Food and Drug Administration (FDA). This meeting is anticipated to facilitate further development of the treatment.
Progress in the company’s Expanded Access Program (EAP), which allows non-trial patients to access the treatment, has encountered delays primarily due to hospital approval processes. However, three sites in New York, North Carolina, and California are now operational, and two patients have begun receiving treatment.
IQ-AI retains full rights to the Phase I trial data and is committed to advancing the drug through subsequent phases. Initial results have shown no toxic side effects and early indications of positive outcomes. The FDA’s Rare Pediatric Disease Designation (RPDD) is also significant, as it may provide a voucher to accelerate regulatory approval, although there are ongoing legislative efforts to extend the program beyond its planned expiration in 2026.
Additionally, the company recently released a promotional video for its IB Nimble device, designed to assist healthcare professionals in managing complex diseases with a mobile solution. IQ-AI is also advancing its AI-driven technology, IB Zero G, which aims to enhance medical imaging for vulnerable patient groups, including children and pregnant women. Regulatory clearance for this product is still pending.
With Phase I trial results and data from the EAP anticipated in early 2025, IQ-AI believes these insights will play a crucial role in shaping its commercialization strategy. In the interim, the company is exploring various funding options to support its growth initiatives.
